New York University · NeuroscienceThe Amyloid Initiative
Henrieta Scholtzova · New York, New York
Research Focus
Dr. Henrieta Scholtzova's lab at NYU School of Medicine is focused on understanding how the immune system can be harnessed to tackle Alzheimer's disease, particularly through a unique approach using the TLR9 pathway. The lab uses squirrel monkeys, which develop age-related amyloid conditions similar to humans, to test new therapies aimed at improving cognitive function and preventing complications that often arise with current treatments. By integrating various biomarker data and advanced imaging techniques, they aim to better understand and treat cerebral amyloid angiopathy, a common risk factor for cognitive decline in Alzheimer's patients.
Alzheimer's Diseaseinnate immunityTLR9cerebral amyloid angiopathybiomarkersproteomicssquirrel monkeysneuroimaging
Research Aims
5AIM 01Explore the effects of TLR9 agonist CpG ODN on cognitive behavior in squirrel monkeys.
AIM 02Characterize biomarkers associated with Alzheimer's disease and cerebral amyloid angiopathy.
AIM 03Assess the safety and efficacy of CpG ODN 1018 through imaging and neuropathological correlates.
AIM 04Investigate immune cell trafficking in response to CpG 1018 treatment.
AIM 05Develop a comprehensive proteomic profile of cerebral amyloid angiopathy and choroid plexus related to treatment outcomes.
Skills the Lab Values
PCRcell culturemouse and squirrel monkey modelsWestern blotimmunohistochemistryMRI imaging techniquesmass spectrometrybioinformaticsliquid chromatographydata analysis techniques
Output against the department
Publications93bottom 30% of dept.467th of 671
this lab
most publishedleast published
Citations3.0kbottom 22% of dept.523rd of 671
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.